Author: Ravi Shankar

ORLANDO, Fla., Oct. 23, 2026 (GLOBE NEWSWIRE) — IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2026 third quarter financial results before the market opens on Friday, October 30, 2026. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.

Individuals interested in participating in the conference call may do so by registering here, https://register-conf.media-server.com/register/BI7e9cb633a38e45258f691f2b6d592419 Once registered, a dial-in number, unique pin, and instructions will be provided to participants.
The conference call will also be available real-time via the internet at http://www.iradimed.com/en-us/investors/events/. A recording of the call will be available on the Company’s website following the completion of the call.

About IRADIMED CORPORATION

IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance Imaging (“MRI”) compatible medical devices. We design, manufacture, market, and distribute MRI-compatible medical devices, accessories, disposables, and related services.

We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components that can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI compatible IV infusion pump systems (3860 and 3870) have a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts, and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solutions provide a seamless approach that enables accurate, safe, and dependable fluid delivery before, during, and after an MRI scan, which is essential to critically ill patients who cannot be removed from their vital medications and children and infants who must generally be sedated to remain immobile during an MRI scan.

Our 3880 MRI compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The Iradimed 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually anywhere in the MRI scanner room. The Iradimed 3880 has a compact, lightweight design, allowing it to travel with the patient from the critical care unit to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the Iradimed 3880 include wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The Iradimed 3880 MRI compatible patient vital signs monitoring system has an easy-to-use design and allows for the effective communication of patient vital signs information to clinicians.

For more information, please visit www.iradimed.com. 

Media Contact:
John Glenn
Chief Financial Officer
iRadimed Corporation
(407) 677-8022
InvestorRelations@iradimed.com

AI-powered assistant helps public safety professionals turn complex operational data into faster insights and better-informed decisions

ORLANDO, Fla., Oct. 23, 2026 (GLOBE NEWSWIRE) — SoundThinking, Inc. (Nasdaq: SSTI), a leading public safety technology provider, today announced the general availability of SafetySmart® Field Agent to all ShotSpotter agencies, marking the transition from the beta program announced in June to broader commercial availability. SoundThinking is making Field Agent available to ShotSpotter agencies at no additional charge for up to 20 users per agency during the first year.

Introduced earlier this year with more than 20 beta agencies, Field Agent helps public safety personnel turn operational information into actionable insights without overburdening limited analyst resources. Using natural-language questions, personnel can analyze ShotSpotter data, identify trends, and generate maps, charts, incident summaries and draft briefings. By combining analysis and reporting in a single conversational experience, Field Agent reduces manual tasks and helps personnel across the agency make better-informed operational decisions.

“Field Agent represents a new way for public safety professionals to put ShotSpotter intelligence to work,” said Ralph Clark, President and CEO of SoundThinking. “By making it easier to analyze gunfire activity, uncover patterns and generate actionable insights, we’re helping agencies make faster, better-informed decisions. And as we expand Field Agent to additional sources of operational data, we see even greater opportunities to bring the power of AI into everyday public safety operations.”

The potential applications extend across agency operations. For example, a police chief responding to questions from city leadership could ask Field Agent how gunfire activity has changed over the past month and receive charts and maps highlighting relevant trends. Similarly, a supervisor preparing for an upcoming shift could request a summary of recent gunfire incidents in a specific patrol area, including locations and time-of-day patterns, to help inform operational planning and deployment decisions.

SoundThinking is also developing Field Agent Skills, a new capability that will allow agencies to create reusable instructions for recurring tasks, such as preparing shift briefings and summarizing incident activity, saving time and improving consistency.

“Field Agent is helping us get more value from information we already have,” said Detective Lucas Roethlisberger, Intelligence Unit / Crime Gun Intelligence Center, St. Louis Metropolitan Police Department. “Instead of waiting for someone to pull data and build an analysis, our team can ask questions directly, identify patterns, and get useful insights much faster. What’s especially exciting is the potential to bring more of our operational data into that experience, giving our people a more complete picture to support better-informed decisions.”

Looking ahead, SoundThinking is expanding the types of information Field Agent can use to support operational decision-making. The company is testing additional agency data sources, including computer-aided dispatch (CAD) and records management system (RMS) information, while enabling agencies to incorporate relevant information through documents and spreadsheets.

SoundThinking is also developing integration with CrimeTracer, its law enforcement search engine, which will extend Field Agent’s capabilities to additional investigative and criminal justice information and create opportunities to bring AI-powered decision support to CrimeTracer’s extensive network of over 2,100 agencies. Beta availability is planned for November, with general availability targeted for early 2027.

As Field Agent expands across additional agency data sources, responsible AI remains foundational to its design. Human review and decision-making remain central to the workflow: the technology can accelerate searching, synthesis and analysis, but interpretation, validation and operational or investigative decisions remain with authorized personnel.

ShotSpotter agencies can contact their Customer Success Director or email support@soundthinking.com to activate Field Agent access. Attendees at the International Association of Chiefs of Police (IACP) Annual Conference and Exposition in Orlando, Fla., can see a demonstration at Booth 1109 during the exposition, Oct. 25–27, 2026.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the potential application and effectiveness of Field Agent and the timing of availability of Field Agent’s integration with CrimeTracer. Words such as “expect,” “anticipate,” “should,” “believe,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “could,” “intend,” or variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the company’s control. The company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the effect of the announcement of the potential acquisition of the company on the company’s business relationships, including with partners, customers and employees; the diversion of the company’s management’s time and attention from ongoing business operations and opportunities; the impact of global macroeconomic conditions on the company’s business; as well as other risk factors included in the company’s most recent annual report on Form 10-K and other SEC filings. These forward-looking statements are made as of the date of this press release and are based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Except as required by law, the company undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events or changes in its expectations.

About SoundThinking
SoundThinking, Inc. (Nasdaq: SSTI) is a leading public safety technology company that delivers AI- and data-driven solutions for law enforcement, civic leadership, and security professionals. SoundThinking is trusted by approximately 300 customers and supports approximately 2,100 agencies to drive more efficient, effective, and equitable public safety outcomes. The company’s SafetySmart® platform includes ShotSpotter®, the leading acoustic gunshot detection system; CrimeTracer™, the leading law enforcement search engine; SafePointe®, an AI-based weapons detection system; PlateRanger™ (powered by Rekor®), a leading ALPR solution; and Field Agent, an AI layer that transforms public safety data into actionable intelligence. SoundThinking has been designated a Great Place to Work® Company.

Company Contact:
Alan Stewart, CFO
SoundThinking, Inc.
+1 (510) 794-3100
astewart@soundthinking.com

Investor Relations Contact:
Ankit Hira
Solebury Strategic Communications for SoundThinking, Inc.
+1 (203) 546-0444
SSTI@soleburystrat.com

Source: SoundThinking, Inc.

 — Patient demographics consistent with prior studies of other agents in HCM and reflect real-world clinical practice —

— Mean baseline KCCQ-CSS of 59 shows considerable symptom burden at study entry –

                  — Substantial over enrollment strengthens statistical power and provides robust dataset to evaluate the efficacy and safety of sotagliflozin —

THE WOODLANDS, Texas, Oct. 23, 2026 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today provided an update on the baseline characteristics of the patients randomized into the ongoing pivotal Phase 3 SOtaglifloziN in Patients with SymptomATic obstructive And non-obstructive Hypertrophic CardioMyopathy (SONATA-HCM) clinical trial evaluating sotagliflozin in patients with symptomatic hypertrophic cardiomyopathy. The data will be presented in detail by Dr. Sharlene Day, M.D., Presidential Professor, Director of Translational Research of the Penn Cardiovascular Institute, University of Pennsylvania and co-chair of the SONATA-HCM steering committee, on Saturday, October 24, 2026, at 4:05 p.m. ET at the International HCM Summit in Boston, MA.

The patient enrollment profile of SONATA-HCM is consistent with the study’s inclusive design, which aimed to reflect real-world clinical practice. Patients were permitted to remain on stable background therapies, including cardiac myosin inhibitors, allowing evaluation of sotagliflozin in patients receiving currently available HCM treatments. Importantly, baseline demographic and clinical characteristics within both the non-obstructive (nHCM) and obstructive HCM (oHCM) cohorts were generally consistent with those reported in previous clinical studies of other agents in those respective patient populations, supporting the relevance of the SONATA-HCM study population to the broader HCM community.

In total, SONATA-HCM enrolled 542 patients across more than 130 sites in 20 countries, substantially exceeding the study’s target enrollment of 500 patients and a providing larger dataset that may further enhance the statistical power of the study to detect meaningful treatment effects on its primary efficacy endpoint. Among enrolled patients, 440 have nHCM and 102 have oHCM, positioning SONATA-HCM to evaluate sotagliflozin in a broad HCM population while emphasizing patients with non-obstructive disease, who currently have no FDA-approved disease-specific treatments.

The overall study population had a mean baseline Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) of 59, reflecting a considerable burden of symptoms and limitations in daily activities at study entry. KCCQ-CSS ranges from 0 to 100, with higher scores indicating better health status and fewer symptoms, demonstrating that the SONATA-HCM study population began the trial with substantial opportunity for improvement. The primary efficacy endpoint of the pivotal study is improvement in symptoms, as measured by change from baseline in KCCQ-CSS at Week 26.

“We designed SONATA-HCM to evaluate sotagliflozin in a broad and clinically relevant HCM population reflective of real-world clinical practice, and we are very pleased that the final study population met that objective,” said Craig Granowitz, M.D., Ph.D., senior vice president and chief medical officer of Lexicon. “The demographic and clinical characteristics of both the obstructive and non-obstructive HCM cohorts were generally consistent with those reported in previous studies of other agents, while the baseline KCCQ score reflects a population with meaningful symptom burden. Combined with the substantial over enrollment and representation of both major HCM subtypes, we believe SONATA-HCM is well positioned to evaluate sotagliflozin across the broad spectrum of symptomatic HCM patients.”

SONATA-HCM is the only ongoing Phase 3 study in both nHCM and oHCM and is the largest Phase 3 study including both nHCM and oHCM to date. Topline results are anticipated in the first quarter of 2027.

About Sotagliflozin
Discovered using Lexicon’s unique approach to gene science, sotagliflozin is an oral inhibitor of two proteins responsible for glucose regulation known as sodium-glucose cotransporter types 2 and 1 (SGLT2 and SGLT1). SGLT2 is responsible for glucose and sodium reabsorption by the kidney and SGLT1 is responsible for glucose and sodium absorption in the gastrointestinal tract and the heart. Sotagliflozin has been studied in multiple patient populations encompassing heart failure, diabetes, and chronic kidney disease in clinical studies involving approximately 20,000 patients. Sotagliflozin is also currently under investigation for hypertrophic cardiomyopathy (HCM).

About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals is a biopharmaceutical company pursuing novel medicines for patients with serious cardiometabolic diseases. Building on a proven legacy in genetic target discovery, Lexicon is advancing a clinical pipeline in areas of significant and often underserved need, with programs in hypertrophic cardiomyopathy (HCM), type 1 diabetes (T1D), obesity and other related metabolic conditions. Lexicon is committed to developing differentiated therapies that can be integrated broadly into clinical practice, with the goal of expanding treatment options for patients. Its capabilities extend from early-stage target discovery through clinical development and commercialization, strategically paired with high-impact collaborations to maximize the global reach of its medicines.

For additional information, please visit www.lexpharma.com.   

Safe Harbor Statement
This press release contains “forward-looking statements,” including statements relating to the research, development and therapeutic and commercial potential of sotagliflozin in hypertrophic cardiomyopathy. In addition, this press release may also contain forward-looking statements relating to Lexicon’s financial position and long-term outlook on its business, including the commercialization of its approved products and the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of its other drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery, development and commercialization of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully commercialize its approved products, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its approved products and other drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

For Media Inquiries:
Dave Belian
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com

For Investor Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com

SELANGOR, Malaysia, Oct. 23, 2026 (GLOBE NEWSWIRE) — Founder Group Limited (NASDAQ: FGL) (“FGL” or the “Company”) today announced that it received a letter dated October 19, 2026 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with Nasdaq’s minimum publicly held shares requirement under Listing Rule 5550(a)(4) (the “Listing Rule”).

Nasdaq previously notified the Company on September 16, 2026 that it did not comply with the minimum 500,000 publicly held shares requirement for The Nasdaq Capital Market under the Listing Rule. Based on the Company’s confirmation dated October 9, 2026 that it has 541,791 publicly held shares, Nasdaq determined that the Company complies with the Listing Rule and that this matter is now closed.

About Founder Group Limited 

Founder Group Limited is a pure-play, end-to-end EPCC solutions provider for solar PV facilities in Malaysia. The company’s primary focus is on two key segments: large-scale solar projects and commercial and industrial (C&I) solar projects. The company’s mission is to provide customers with innovative solar installation services, promote eco-friendly resources and achieve carbon neutrality.

For more information on the Company, please visit https://www.founderenergy.com.my/.

Safe Harbor Statement

This press release contains forward-looking statements that reflect our current expectations and views of future events. Known and unknown risks, uncertainties and other factors, including those listed under “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission, may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. You can identify some of these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,” “continue” or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements involve various risks and uncertainties. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. We qualify all of our forward-looking statements by these cautionary statements.

Contact Information

For media queries, please contact:

Founder Group Limited
info@founderenergy.com.my

Acquisition accelerates House of Doge’s expansion into tokenized alternative investments and on-chain yield, company investigating financing alternatives, plans to seek stockholder approval for a reverse split of its common stock.

MIAMI, Oct. 23, 2026 (GLOBE NEWSWIRE) — House of Doge Inc. (NASDAQ: HODO) today announced an agreement to acquire the tokenization platform and credit assets of McQueen Labs Inc., marking a major push into the $51 billion tokenized real-world asset market and accelerating plans to introduce tokenized yield vaults that put real-world credit assets to work on blockchain rails.

The acquisition marks the beginning of a new chapter for House of Doge, as the company sharpens its focus on tokenized alternative investments and on-chain yield. A forthcoming corporate rebrand is also part of the company’s plans, with additional strategic announcements expected in the months ahead. As part of the announced transaction, Mr. Curt Hopkins, CEO of McQueen Labs, will be appointed interim CEO and CFO of House of Doge, Inc. Following the closing, it is anticipated that Mr. Hopkins’s CEO appointment will be made permanent, while a search will be conducted for a CFO.

Supporting this strategic expansion, House of Doge is examining financing alternatives to pursue growth opportunities, accelerate its tokenization strategy, and support its broader ambitions in digital finance. In addition, the company expects to file a proxy statement in the near future in connection with its annual meeting of stockholders, which will include a proposal to approve the reverse split of its common stock.

A $51 Billion Market Opportunity

Tokenization is transforming how real-world assets are owned, traded, and used in financial markets. According to Bernstein Research data reported by Cointelegraph in May 2026, the tokenized real-world asset market reached approximately $51 billion, growing 42% year to date, with private credit accounting for roughly 44% of the market.

House of Doge aims to capitalize on this momentum by moving beyond tokenized ownership into tokenized yield vaults, designed to unlock new opportunities for generating yield from real-world assets.

“This acquisition marks an important step toward the future we’re building,” said Sarosh Mistry, Chairman of House of Doge. “McQueen Labs brings the technology and assets to accelerate our vision for tokenized yield vaults and alternative investments. With a new corporate identity, a sharper strategic focus, and more developments ahead, we’re laying the groundwork for the next phase of our growth.”

“Investors globally are seeking higher yields, yet traditional markets often fail to adequately compensate them for liquidity, credit, and duration risk,” said Curt Hopkins, CEO of McQueen Labs and newly appointed interim CEO and CFO of House of Doge Inc. “Tokenized private credit and blockchain-based lending secured by these assets represent an enormous market opportunity. At McQueen Labs, we’ve built a leading tokenization platform focused on high-demand alternative assets historically inaccessible to most investors. Joining forces with House of Doge will accelerate our growth, expand distribution, and open the door to new asset classes.”

Tokenized Yield Vaults: Putting Real-World Assets to Work

At the center of House of Doge’s expansion are tokenized yield vaults, structured blockchain-based products designed to accept tokenized credit assets as collateral and create new opportunities to access yield from income-producing alternative investments.

By combining real-world credit assets with blockchain-based financial infrastructure, House of Doge aims to move beyond simply tokenizing ownership, creating products that enable tokenized assets to be used within a broader on-chain financial ecosystem.

McQueen Labs, operator of MCQ Markets, developed its tokenization platform to enable fractional ownership of high-value collector cars, private credit and future alternative asset classes. House of Doge plans to leverage this infrastructure and the acquired credit assets to accelerate the development of its vault offerings and expand into tokenized credit, sports investments and yield-oriented products.

The acquisition complements House of Doge’s existing strategic interests in professional sports franchises and advances its focus on building a platform for tokenized alternative investments.

Transaction terms and the anticipated launch timeline for the yield vaults have not yet been disclosed. Further details regarding the corporate rebrand, share consolidation, and additional strategic initiatives will be announced separately.

Leadership Transition

House of Doge also announced that Marco Margiotta, its Chief Executive Officer, and Charles Park, its Chief Financial Officer, have resigned from their positions, effective October 22, 2026. House of Doge thanks Mr. Margiotta and Mr. Parks for their contributions to the company.

Effective immediately, Curt Hopkins, Chief Executive Officer of McQueen Labs, has been appointed to serve as Interim Chief Executive Officer and Interim Chief Financial Officer of House of Doge.

About House of Doge

House of Doge Inc. (NASDAQ: HODO) is building the next generation of alternative investing, combining blockchain innovation with real-world assets to unlock new opportunities for investors. With a growing portfolio spanning tokenized investments, digital finance, and strategic interests in professional sports franchises, the company is focused on transforming how alternative assets are accessed, owned, and monetized.

About McQueen Labs

McQueen Labs Inc. is pioneering tokenized real-world assets with an integrated platform unlocking access, liquidity, and investment opportunities across traditionally exclusive asset classes. Through its flagship platform, MCQ Markets, the company has launched SEC-qualified fractional investment offerings in high-value collector cars, achieving multiple successful exits with double-digit investor returns. Its capabilities span private credit, tokenized lending, and alternative assets, combining investment expertise with blockchain technology to advance the next generation of capital markets.

STATEMENT REGARDING FORWARD-LOOKING INFORMATION

Information and statements contained in this news release that are not historical facts constitute “forward-looking information” and “forward-looking statements” involving risks and uncertainties relating to House of Doge’s current expectations, intentions, plans and beliefs. Forward-looking information can often be identified by words such as “anticipate,” “believe,” “expect,” “goal,” “plan,” “target,” “intend,” “estimate,” “could,” “should,” “may” and “will,” or the negative of these terms or similar expressions suggesting future outcomes, events or performance.

Examples of forward-looking information in this news release include, without limitation: completing the proposed acquisition of McQueen Labs’ tokenization platform and credit assets and satisfying applicable closing conditions; integrating and utilizing the acquired platform and assets; realizing the anticipated benefits of the acquisition, including accelerated growth, expanded distribution and access to additional asset classes; developing and introducing tokenized yield vaults that accept tokenized credit assets as collateral; creating opportunities to access yield from income-producing alternative investments; expanding into tokenized credit, sports investments and yield-oriented products; building a broader platform for tokenized alternative investments and on-chain financial activity; establishing and utilizing a proposed $100 million at-the-market equity offering program to support growth and strategic initiatives; completing a corporate rebrand and share consolidation; and announcing further details regarding these initiatives and the anticipated launch timeline for the yield vaults. Forward-looking information also includes expectations regarding the growth and potential of the tokenized real-world asset market and the Company’s ability to capitalize on those opportunities.

These statements are based on assumptions that may change or prove incorrect, including assumptions regarding the completion of the proposed acquisition, the successful integration and performance of the acquired platform and credit assets, the availability of financing on acceptable terms, investor demand, market conditions, applicable regulatory requirements and approvals, and the Company’s ability to develop and launch its planned products and execute its strategy.

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that could cause actual results, performance or achievements to differ materially from those expressed or implied. These include the risk that the proposed acquisition may not close on the anticipated terms or at all; integration and execution challenges; adverse market or regulatory developments; credit defaults, collateral valuation changes and liquidity constraints; technology, blockchain, smart contract and cybersecurity risks; an inability to establish or raise capital through the proposed at-the-market equity offering program; dilution resulting from equity issuances; delays in obtaining necessary approvals or developing and launching products; and the possibility that the corporate rebrand, share consolidation or other planned initiatives may be delayed or not completed.

Readers should not place undue reliance on forward-looking information. Actual results may differ materially from expectations, and there can be no assurance that the proposed acquisition, planned products, financing initiatives or other strategic objectives will be completed or achieve their intended benefits, or that any yield-oriented products will generate positive returns. Forward-looking information is provided as of the date of this news release. House of Doge undertakes no obligation to publicly update or otherwise revise any forward-looking information, except as required by applicable law.

Media Contacts

press@houseofdoge.com

press@mcqmarkets.com

Golar LNG Limited is pleased to announce the publication of its 2025 Environment, Social and Governance Report.

During 2025, our operating FLNG fleet grew and production increased. Amongst several achievements across the metrics we track, we recorded a record-low level of retainage on the fully utilised Gimi, while Hilli continued to deliver market-leading operational performance. LNG was produced more efficiently with both FLNGs outperforming their already competitively low carbon-intensity targets as a result.

Further details on our performance across our five key focus areas—Health, Safety and Security; Environmental Impact; People and Communities; Innovation and Transition; and Governance and Ethics—are available in our 2025 report on our website here.

FORWARD LOOKING STATEMENTS

This press release contains forward-looking statements (as defined in Section 21E of the Securities Exchange Act of 1934, as amended).  All statements, other than statements of historical facts, that address activities and events that will, should, could or may occur in the future are forward-looking statements. Words such as “may,” “could,” “should,” “would,” “expect,” “plan,” “anticipate,” “intend,” “forecast,” “believe,” “estimate,” “predict,” “propose,” “potential,” “continue,” or the negative of these terms and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve many risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Golar LNG undertakes no obligation to update publicly any forward-looking statements whether as a result of new information, future events or otherwise, unless required by applicable law.

Hamilton, Bermuda
October 23, 2026
Investor Questions: +44 207 063 7900
Karl Fredrik Staubo – CEO
Eduardo Maranhão – CFO

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Salvatore A. Abbate appointed President and Chief Executive Officer

Third quarter results reflect significant underperformance in Europe

Alvarez & Marsal retained to advise Company on European operations

Withdraws full-year 2026 guidance

ANTIOCH, Tenn., Oct. 23, 2026 (GLOBE NEWSWIRE) — LKQ Corporation (Nasdaq: LKQ) today announced preliminary, unaudited results for the third quarter ended September 30, 2026, as well as leadership and operational actions intended to address recent performance and position the Company for improved execution under new leadership.

Preliminary Third Quarter 2026 Results

Based on preliminary unaudited financials for the third quarter, LKQ expects to report the following:

• Revenue of $3.32 billion, compared with $3.50 billion in the third quarter of 2025
   
• Parts and services organic revenue decline of 5.4%
   
• Net loss¹ of $16 million to $32 million, including $111 million of non-cash impairment charges, compared with net income¹ of $178 million in the third quarter of 2025
   
• Diluted loss per share¹ of $0.06 to $0.12, including $0.42 per share of non-cash impairment charges, compared with diluted EPS of $0.69 in the third quarter of 2025
   
• Adjusted diluted EPS^1,2 of $0.47 to $0.53, compared with $0.84 in the third quarter of 2025
   
• Europe parts and services organic revenue decline of 9.8%; and segment EBITDA margin of 4.1% to 5.1%, compared with 10.0% in the third quarter of 2025

The third quarter results primarily reflect underperformance in the Europe segment, including operational disruptions associated with the ERP implementation in Germany and volume declines in the United Kingdom and Benelux. While Specialty was modestly below expectations, the shortfall was more limited, and North America performed in line with the Company’s expectations despite softer market conditions.

The Company will report full third quarter results on October 29, 2026, and will hold a conference call at that time.

Leadership Changes

LKQ today announced the appointment of Salvatore A. Abbate as President and Chief Executive Officer, effective December 15, 2026. He succeeds Justin Jude, who is departing the Company effective today. Until Mr. Abbate assumes the role of President and Chief Executive Officer, the Company has established an interim Office of the Chief Executive Officer to provide ongoing leadership continuity, consisting of John Mendel, Chairman of the Board, and Sue Gove, Chair of LKQ’s Audit Committee. The Office of the Chief Executive Officer will work closely with LKQ’s leadership team in overseeing the Company’s operations during the interim period.

(1) References in this release to Net (loss) income and Diluted (loss) earnings per share, and the corresponding adjusted figures, reflect amounts from continuing operations attributable to LKQ stockholders.

(2) Non-GAAP measure. See the table accompanying this release that reconciles the actual or forecasted U.S. GAAP measure to the actual or forecasted adjusted measure, which is non-GAAP.

Also effective today, Andy Hamilton is departing his role as President and Managing Director of LKQ Europe. The Board has engaged Alvarez & Marsal (“A&M”) to advise the Company on its European operations, with an initial focus on improving customer service levels, stabilizing operations and strengthening performance and cost discipline across the region.

“LKQ’s performance, particularly in Europe, has fallen significantly short of the Board’s expectations, and the Board is taking decisive action to address it,” said John Mendel, Chairman of the Board. “We have strong conviction in LKQ’s business and its potential to create significant value for shareholders. Sal is a proven operator with a track record of driving performance in complex distribution businesses, and A&M brings deep experience in operational improvement. Together with LKQ’s talented teams, we are focused on improving execution and delivering improved results for our stakeholders.”

Withdrawal of Full-Year 2026 Guidance

Considering the third quarter results in Europe and the appointment of Mr. Abbate as President and Chief Executive Officer, effective December 15, 2026, LKQ is withdrawing its full-year 2026 guidance, which was most recently updated on July 30, 2026.

Strategic Review Update

In connection with the Board’s ongoing review of strategic alternatives, the Company has taken several actions, including appointing Mr. Abbate as the Company’s next President and Chief Executive Officer, implementing leadership changes within its European operations, and retaining A&M to advise the Company with respect to its European operations. The Company will provide additional updates regarding the strategic alternatives process as appropriate.

About LKQ Corporation

LKQ Corporation (www.lkqcorp.com) is a leading provider of alternative and specialty parts to repair and accessorize automobiles and other vehicles. LKQ has operations in North America, Europe and Taiwan. LKQ offers its customers a broad range of OE recycled and aftermarket parts, replacement systems, components, equipment, and services to repair and accessorize automobiles, trucks, and recreational and performance vehicles.

The following unaudited table reconciles Net (Loss) Income and Diluted (Loss) Earnings per Share to Adjusted Net Income and Adjusted Diluted (Loss) Earnings per Share, respectively:

	Three Months Ended September 30,
	2026							2025
	Preliminary
(In millions, except per share data)		Low			High
Net (loss) income	$	(35	)	$	(19	)	$	180
Less: net (loss) income attributable to continuing noncontrolling interest		(1	)		(1	)		—
Net (loss) income attributable to LKQ stockholders		(34	)		(18	)		180
Less: net (loss) income from discontinued operations		(2	)		(2	)		2
Net (loss) income from continuing operations attributable to LKQ stockholders		(32	)		(16	)		178
Adjustments:
Amortization of acquired intangibles		34			34			37
Restructuring and transaction related expenses		24			24			14
Impairment of goodwill		88			88			—
Impairment of net assets held for sale		23			23			—
Direct impacts of Ukraine/Russia conflict		4			4			—
Excess tax deficiency from stock-based payments		1			1			—
Tax effect of adjustments		(23	)		(23	)		(13	)
Adjusted net income	$	119		$	135		$	216
Weighted average diluted common shares o/s		252.9			252.9			257.3
Diluted (loss) earnings per share:
Reported	$	(0.12	)	$	(0.06	)	$	0.69
Adjusted	$	0.47		$	0.53		$	0.84

We have presented Adjusted Net Income and Adjusted Diluted Earnings per Share as we believe these measures are useful for evaluating the core operating performance of our continuing business across reporting periods and in analyzing our historical operating results. We define Adjusted Net Income and Adjusted Diluted Earnings per Share as Net Income and Loss and Diluted Earnings (Loss) per Share adjusted to eliminate the impact of net income and loss attributable to noncontrolling interest, income and loss from discontinued operations, restructuring and transaction related expenses, amortization expense related to all acquired intangible assets, gains and losses on debt extinguishment, changes in fair value of contingent consideration liabilities, other gains and losses related to acquisitions, equity method investments, or divestitures, impairment charges, direct impacts of the Ukraine/Russia conflict, excess tax benefits and deficiencies from stock-based payments and any tax effect of these adjustments. The tax effect of these adjustments is calculated using the effective tax rate for the applicable period or for certain discrete items the specific tax expense or benefit for the adjustment. These financial measures are used by management in its decision making and overall evaluation of our operating performance and are included in the metrics used to determine incentive compensation for our senior management. Adjusted Net Income and Adjusted Diluted Earnings per Share should not be construed as alternatives to Net Income and Loss or Diluted Earnings (Loss) per Share as determined in accordance with accounting principles generally accepted in the United States. In addition, not all companies that report measures similar to Adjusted Net Income and Adjusted Diluted Earnings per Share calculate such measures in the same manner as we do and, accordingly, our calculations are not necessarily comparable to similarly-named measures of other companies and may not be appropriate measures for performance relative to other companies.

Forward-Looking Statements

Statements and information in this press release that are not historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are made pursuant to the “safe harbor” provisions of such Act.

Forward-looking statements include, but are not limited to, statements regarding our outlook, expectations, beliefs, hopes, intentions and strategies. These statements are subject to a number of risks, uncertainties, assumptions and other factors including those identified in our filings with the SEC. All forward-looking statements are based on information available to us at the time the statements are made. We undertake no obligation to update any forward- looking statements, whether as a result of new information, future events or otherwise, except as required by law.

You should not place undue reliance on our forward-looking statements. Actual events or results may differ materially from those expressed or implied in the forward-looking statements. The risks, uncertainties, assumptions and other factors that could cause actual events or results to differ from the events or results predicted or implied by our forward- looking statements include the factors discussed in our filings with the SEC, and other factors discussed in our filings with the SEC, including those disclosed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2025 and in our subsequent Quarterly Reports on Form 10-Q. These reports are available at the Investor Relations section on our website (www.lkqcorp.com) and on the SEC’s website (www.sec.gov). 

Preliminary Financial Information

The preliminary third quarter financial highlights presented in this press release are derived from our internal records and based on the most recent current information available to management, are subject to the closing and finalization of financial and accounting procedures for the period (which have yet to be performed) and should not be viewed as a substitute for our full financial statements prepared in accordance with GAAP. Our normal reporting processes with respect to the preliminary estimated financial data provided in this press release have not been fully completed. As a result, these preliminary estimated results may differ from the actual results that will be reflected in our unaudited condensed consolidated financial statements for the third quarter of 2026 when they are completed. While we believe that these estimates are based on reasonable assumptions, our actual results may vary, and such variations may be material.

Investor Contact

Joseph P. Boutross LKQ Corporation
Vice President, Investor Relations
(312) 621-2793
jpboutross@lkqcorp.com

Media Contact

Whit Clay
Longacre Square Partners
lkq@longacresquare.com

MEDELLÍN, Colombia, Oct. 23, 2026 (GLOBE NEWSWIRE) — Mineros S.A. (TSX: MSA; BVC: MINEROS; OTCQX: MNSAF) (“Mineros” or the “Company”) announces that its Board of Directors has called an extraordinary meeting of shareholders (the “Meeting”). The Meeting will be held at 10:00 a.m. (Colombia time) on November 24, 2026, in the Salón Gran Real of the Hotel Marriott, Calle 1a Sur #43a-83, Medellín, Antioquia, Colombia.

The matters to be voted on or addressed at the Meeting are as follows:

1. Verification of quorum and introduction to the Meeting.
2. Approval of the Meeting agenda.
3. Appointment of the commission for the scrutiny, review and approval of the minutes of the Meeting.
4. Approval of the release of occasional reserves and distribution of the amount released to shareholders as an extraordinary dividend.

Proposed Extraordinary Dividend

At the Meeting, shareholders will be asked to approve the release of a portion of the Company’s occasional reserves, constituted out of profits of fiscal years ended on or before December 31, 2025, and the distribution of the released amount as a one-time extraordinary cash dividend of US$0.20 per common share (the “Extraordinary Dividend”).

If approved, the Extraordinary Dividend will be payable in a single instalment on December 4, 2026, to shareholders of record on December 1, 2026. It is in addition to, and does not affect, the ordinary dividend of US$0.10 per share approved on March 27, 2026. The Board recommends that shareholders vote FOR the resolution.

Dividends paid to shareholders holding through the Canadian system will be subject to a 20% Colombian withholding tax. Eligible shareholders may claim any excess withholding through the procedure described in the Management Information Circular dated October 15, 2026 (the “Circular”).

Meeting Materials and Voting

The record date for shareholders in the Canadian market is October 15, 2026. To be valid, proxies and voting instruction forms must be received by TSX Trust Company no later than 10:00 a.m. (Colombia time) on November 20, 2026.

The Company is using notice-and-access. The Circular and related materials are available on SEDAR+ at www.sedarplus.com, at https://docs.tsxtrust.com/MSA2026, and on the Company’s website at www.mineros.com.co. A live listen-only webcast of the Meeting will be available on the Company’s website.

About Mineros S.A.
Mineros is a leading Latin American gold producer headquartered in Medellín, Colombia. The Company benefits from a diversified asset portfolio, encompassing operating mines in Colombia and Nicaragua, alongside a pipeline of development and exploration projects located throughout the region, including the Porvenir development asset in Nicaragua, the La Pepa Project in Chile and the Tolima Project in Colombia.

With an operating history spanning over 50 years, Mineros is defined by a commitment to safety, sustainability, and disciplined capital allocation. Its common shares are listed on the Toronto Stock Exchange (MSA) and the Colombia Stock Exchange (MINEROS), and trade on the OTCQX® Best Market under the symbol MNSAF.

For Further Information
Ann Wilkinson | Vice President, Investor Relations
+1 (647) 496-3011 | Ann.Wilkinson@Mineros.com.co

Juan Camilo Obando | Director, Investor Relations
(+57) 604 266 5757 | Juan.Obando@Mineros.com.co

Forward-Looking Statements
This news release contains forward-looking information within the meaning of applicable Canadian securities laws, including statements with respect to the approval, declaration, timing, amount and payment of the Extraordinary Dividend, the amount of occasional reserves available for distribution, the expected tax treatment of the Extraordinary Dividend. Forward-looking information is based upon estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this news release including, without limitation, assumptions about: the approval of the Extraordinary Dividend by the General Shareholders Assembly; the Company’s financial condition, liquidity and cash flows; the absence of restrictions on the payment of dividends under the Company’s financing arrangements; legal, regulatory and tax stability in Colombia and Canada; and the number of common shares outstanding on the record date. While the Company considers these assumptions to be reasonable, the assumptions are inherently subject to significant business, social, economic, political, regulatory, competitive and other risks and uncertainties, contingencies and other factors that could cause actual actions, events, conditions, results, performance or achievements to be materially different from those projected in the forward-looking information. Forward-looking information involves known and unknown risks, uncertainties and other factors, and does not guarantee future performance. Risks and uncertainties that may cause actual results or developments to be materially different from those expressed in forward-looking information include, without limitation: the General Shareholders Assembly may not approve the Extraordinary Dividend, or may approve it with variations; laws, regulations and tax rates may change; and the Company’s financing arrangements may restrict the payment of dividends. This list is not exhaustive. There can be no assurance that forward-looking information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. Forward-looking information contained herein is made as of the date of this news release. The Company disclaims any obligation to update or revise any forward-looking information, except as required by applicable securities laws.

HONG KONG, Oct. 23, 2026 (GLOBE NEWSWIRE) — 3 E Network Technology Group Limited (Nasdaq: MASK) (the “Company” or “3 E Network”), a business-to-business (“B2B”) information technology (“IT”) business solutions provider, committed to becoming a next-generation artificial intelligence (“AI”) infrastructure solutions provider, today entered into a subscription agreement (the “Subscription Agreement”) with 3E NETWORK TECHNOLOGY PTE. LTD., a company incorporated under the laws of Singapore (the “Yang Investor”), and six individual purchasers (collectively with the Yang Investor, the “Purchasers”), for a private placement (the “Private Placement”) of an aggregate of 2,751,789 Class A ordinary shares, par value $0.005 per share, of the Company (the “Class A Ordinary Shares”), at a purchase price of approximately US$1.8170 per share, for aggregate gross cash proceeds to the Company of $5,000,000. On October 23, 2026, the Company announced a two-for-one share consolidation, with its Class A Ordinary Shares expected to begin trading on a post-consolidation basis on October 30, 2026 (the “Nasdaq Market Effective Date”). These share numbers, the par value and the per-share purchase price are stated on a post-consolidation basis.

Under the Subscription Agreement, the Yang Investor agreed to subscribe for 1,157,823 Class A Ordinary Shares for $2,103,764.12, and each of the six individual purchasers agreed to subscribe for 265,661 Class A Ordinary Shares for $482,705.98, in each case on a post-consolidation basis. Each Purchaser’s obligations are several and not joint. The issuance of the Class A Ordinary Shares under the Subscription Agreement is subject to satisfaction of the applicable conditions thereunder and will not occur before the Nasdaq Market Effective Date.

The Class A Ordinary Shares to be issued and sold under the Subscription Agreement will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), and will be offered and sold in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D thereunder. The Company is relying on such exemption based in part on the Purchasers’ representations, including that each Purchaser is an accredited investor. The Class A Ordinary Shares may not be offered or sold absent registration or an applicable exemption from registration requirements. Neither this press release nor the related Report on Form 6-K constitutes an offer to sell or the solicitation of an offer to buy the securities described herein.

The Yang Investor is controlled by Dr. Tingjun Yang (“Dr. Yang”), the Company’s Chief Executive Officer and a director, and its subscription in the Private Placement constitutes a related-party transaction. The Audit Committee of the Board of Directors reviewed and approved the Private Placement, including the Yang Investor’s participation as a related-party transaction, and recommended approval by the Board of Directors. The Board of Directors approved the Private Placement and the transactions contemplated by the Subscription Agreement. Other than the Yang Investor, none of the Purchasers has any affiliation with or other interest relationship with the Company or its directors or officers.

The Company intends to use the proceeds from the Private Placement for general working capital, ordinary course business operations and other lawful corporate purposes determined by the Company in its reasonable discretion, in compliance with applicable laws and regulations.

About 3 E Network Technology Group Limited
3 E Network Technology Group Limited is a business-to-business (“B2B”) information technology (“IT”) business solutions provider committed to becoming a next-generation artificial intelligence (“AI”) infrastructure solutions provider. It upholds the industry consensus of “AI and energy symbiosis” and has a strong vision in the field of energy investment. The Company’s business comprises two main portfolios: the data center operation services portfolio and the software development portfolio. For more information, please visit the Company’s website at https://3emask.com/.

Forward-Looking Statements
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “assesses,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect the Company’s future results in the Company’s registration statement and other filings with the U.S. Securities and Exchange Commission.

For more information, please contact:

3 E Network Technology Group Limited
Investor Relations Department
Email: ird@3emask.com
Website: https://3emask.com/

Preclinical data demonstrate tumor response with AVA6103 in the setting of Enhertu^®-resistance

Potential for prolonged responses with increased FAP+ fibroblasts recruited to the tumor during treatment with AVA6103

LONDON and PHILADELPHIA, Oct. 23, 2026 (GLOBE NEWSWIRE) — Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a life sciences company developing innovative, targeted oncology drugs, today announces the presentation at the European Society for Medical Oncology (ESMO) Congress of the FOCUS-01 Phase 1 clinical trial design and substantial progress in the preclinical arena. AVA6103 is the first Next-Generation pre|CISION^® controlled-release peptide-drug conjugate platform (PDC), a fibroblast activation protein (FAP)-activated exatecan (Exd) PDC, designed to deliver payload to tumors with similar kinetics of antibody drug conjugates (ADCs) using small molecule chemistry.

AVA6103 is designed to significantly increase the therapeutic window of its highly potent payload, exatecan, a topoisomerase 1 inhibitor (TOP1i) similar to the deruxtecan payload of Enhertu^®. The Company highlights preclinical data demonstrating superior disease control by AVA6103 compared with Enhertu^® in a patient-derived xenograft (PDX) mouse model with HER2+/FAP+ gastric tumors that progressed after initial treatment with Enhertu^®, resulting from enhanced cleavage potential with recruitment of FAP+ fibroblasts during treatment with AVA6103.

Dave Liebowitz, Chief Medical Officer of Avacta, commented:

“AVA6103’s continued ability to shrink HER2+ gastric tumors after progression on Enhertu^® demonstrates the potential of pre|CISION^® PDCs to deliver sustained antitumor activity in preclinical models, well beyond the time points achievable with ADCs, showing the potential to improve outcomes for patients with aggressive cancers.

These results add to a growing body of evidence suggesting that pre|CISION^® PDCs are not vulnerable to antigen loss, a phenomenon known to limit the efficacy of ADCs such as Enhertu^® over time, which is demonstrated here in our results. We observed persistent expression of FAP in the tumor through fibroblast recruitment, which is most likely mechanism for increased payload delivery over time on treatment.”

“These findings build further on our initial Phase 1a data with AVA6103 demonstrating proof of mechanism, with a clean safety profile thus far and exceptional alignment between preclinical modeled and clinical pharmacokinetic data, with controlled exatecan release evident in patients for days after dosing. The FOCUS-01 trial continues to progress well towards tumor PK in late Q4 2026 or early Q1 2027 and the first efficacy data, which we expect in H1 2027.”

Alexander Spira MD, PhD, FACP, FASCO, Lead author at ESMO, Co-Director, Virginia Cancer Specialists (VCS) Research Institute and one of the lead investigators of the trial, commented:

“The FOCUS-01 trial is moving rapidly and we are happy to partner with Avacta on this exciting new drug. The preclinical and translational data we have seen thus far reinforce our excitement around this mechanism of action.”

Key Preclinical and Translational Findings with AVA6103

Preclinical data demonstrate that AVA6103 is shows better antitumor activity than Enhertu^® in FAP-positive / HER2-positive disease, including in advanced and resistant tumors.

• In an early stage model (animals randomized once tumors reach 100-200mm³), all AVA6103-treated animals achieved partial responses, with tumor growth inhibition more than double that of Enhertu^®
• In animals with large established tumors (randomized at 400-500mm³), AVA6103 inhibited tumor growth and achieved partial responses, while Enhertu^® demonstrated limited activity
• All AVA6103-treated animals that had previously progressed on Enhertu achieved stable disease, while all animals retreated with Enhertu^® progressed

Tumor tissue studies from this experiment demonstrate that tumors treated with AVA6103 have increased FAP expression over time via immunohistochemistry, with recruitment of FAP+ fibroblasts over the course of treatment. Transcriptomic analysis via RNA seq studies revealed that AVA6103 induced a coordinated inflammatory, wound-healing response, with an upregulation of pathways involved with damage repair, cell cycle arrest, and extracellular matrix (ECM) reorganization.

FOCUS-01: Trial in Progress

The FOCUS-01 Phase 1a trial is a first in-human, multicenter dose escalation trial of AVA6103 and is enrolling patients with select tumor types predicted to be sensitive to the payload exatecan, based on co-expression of FAP and SLFN11, a gene known to predict response to the Topoisomerase 1 inhibitor mechanism.

Preliminary safety and pharmacokinetic (PK) data from the first three dose levels of the FOCUS-01 trial, reported in September, demonstrated proof of mechanism in patients treated in the first three cohorts in the trial. AVA6103 demonstrated a favorable safety profile and was well tolerated through the first three dose levels up to a payload dose approximately 50% higher than the maximum tolerated dose (MTD) of conventional exatecan.

The pharmacokinetic data of the PDC, released peptide and released exatecan patients were remarkably consistent with predictive PK modelling based on preclinical data, greatly increasing confidence that the safety profile, tumor selectivity and antitumor efficacy observed in the preclinical studies of AVA6103 will translate into the clinic.

Enrollment is ongoing in both arms of the study, with enrollment completed at dose level 4, representing an absolute dose of payload that is more than double the maximum tolerated dose (MTD) of conventional exatecan and approaches the equivalent topoisomerase I inhibitor payload dose of the approved dose of Enhertu^® in breast cancer.

Details of the poster presentation

A phase I trial of FAP-Exd (AVA6103), a Fibroblast Activation Protein (FAP)-enabled pre|CISION^® peptide-drug conjugate delivering sustained tumor microenvironment (TME) release of exatecan in patients with FAP-positive solid tumors
Authors: Alexander I. Spira, Nehal J. Lakhani, Judy S. Wang, Muhammad R. Khawaja, Ruairidh Edwards, Karen Campbell, Curtis Rink, Christiana Nikolova, David Liebowitz
Poster number: 1134eTiP

The poster can be found on Avacta’s website here.

Enhertu^® (trastuzumab deruxtecan; T-DXd) is a protease cleavable-linker ADC, approved for both breast cancer and gastric cancer indications (an AstraZeneca/Daiichi Sankyo product). Enhertu^® is a registered trademark of Daiichi Sankyo Company, Limited and AstraZeneca.

For further information from Avacta, please contact:

Avacta Group plc Christina Coughlin, Chief Executive Officer	https://avacta.com/ via Cohesion Bureau
Strand Hanson Limited (Nominated Adviser) James Harris / Chris Raggett / James Dance	www.strandhanson.co.uk
Zeus (Broker) James Hornigold / George Duxberry (Investment Banking) Dominic King / Alex Bartram (Corporate Broking)	www.zeuscapital.co.uk
Cohesion Bureau Communications / Media / Investors Chris Maggos	avacta@cohesionbureau.com

About Avacta – https://avacta.com/

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies through its proprietary pre|CISION^® platform. pre|CISION^® is a payload delivery system based on a tumor-specific protease (Fibroblast Activation Protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Avacta’s innovative pre|CISION^® peptide drug conjugates (PDC) are a novel entry to the XDC drug class, leveraging the success of antibody drug conjugates with alternative methods of delivery beyond antibodies.

Our pre|CISION^® PDCs leverage this tumor-specific release mechanism in a small molecule format to provide unique benefits over traditional antibody drug conjugates (ADC), releasing active payload in the tumor and reducing systemic exposure and toxicity which enables dosing to be optimized to deliver the best outcomes for patients. The lead clinical program is AVA6103, a Next Generation FAP-enabled controlled release pre|CISION^® version of exatecan that delivers the payload directly in the tumor with limited peripheral blood exposure and is currently in clinical development as a treatment for tumor types sensitive to exatecan including cervical cancer, HR+ breast cancer, small cell lung cancer, gastric cancer, colorectal cancer and pancreatic cancer.

About FAP-Exd (AVA6103)

AVA6103 is the second clinical candidate and is the first asset in the pipeline based on the Next Generation innovative pre|CISION^® controlled release mechanism that provides for prolonged release of payload directly in the tumor, minimizing systemic exposure. AVA6103 is being evaluated in the FOCUS-01 Phase 1 trial (FAP-Exd in Oncologic Cancers with Unmet needS). Preclinical data suggest this approach has optimized payload delivery with a high intratumoral concentration and prolonged exposure of released payload in the tumor, coupled with limited systemic exposure to the released payload. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.